Compare ZYME & INSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZYME | INSP |
|---|---|---|
| Founded | 2003 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.2B |
| IPO Year | 2022 | 2018 |
| Metric | ZYME | INSP |
|---|---|---|
| Price | $23.23 | $64.63 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 16 |
| Target Price | $32.75 | ★ $102.86 |
| AVG Volume (30 Days) | 484.1K | ★ 1.4M |
| Earning Date | 03-30-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 5.81 | ★ 179.43 |
| EPS | N/A | ★ 4.89 |
| Revenue | $76,304,000.00 | ★ $82,050,000.00 |
| Revenue This Year | $63.10 | $8.70 |
| Revenue Next Year | $93.26 | $9.05 |
| P/E Ratio | ★ N/A | $14.01 |
| Revenue Growth | 0.38 | ★ 62.18 |
| 52 Week Low | $9.03 | $53.11 |
| 52 Week High | $28.49 | $189.49 |
| Indicator | ZYME | INSP |
|---|---|---|
| Relative Strength Index (RSI) | 49.13 | 42.02 |
| Support Level | $22.22 | $53.11 |
| Resistance Level | $23.66 | $83.68 |
| Average True Range (ATR) | 0.84 | 5.35 |
| MACD | 0.15 | 1.43 |
| Stochastic Oscillator | 45.85 | 35.03 |
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and Europe wherein, it generates a majority of its revenue from the United States.